Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the intracellular delivery of RNase A-QPN using a novel type of lipid-based nanoparticles, and subsequent protein activation by cellular NQO1, selectively inhibit cancer cell growth in vitro and effectively suppress tumor growth in vivo.
|
31589435 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that NQO1 was frequently up-regulated in human liver cancer, and its high expression level was correlated with the tumor stage and low survival rate of HCC patients.
|
30867140 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control.
|
31324798 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we used NQO1-knockout (KO) mice to investigate the role of NQO1 in both the aging process and tumor susceptibility, specifically in the context of CR.
|
29733330 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Release of Lapa selectively increases tumor site-specific generation of H<sub>2</sub>O<sub>2</sub> via NAD(P)H: quinone oxidoreductase 1 (NQO1) catalysis.
|
31397998 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
When the NQO1-proficient A549 tumors and NQO1-deficient MDA-MB-231 tumors were developed in the same animal, only the A549 malignancies activated the NIR-ASM probe with a strong signal.
|
31189950 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Low NQO1 mRNA and protein levels were observed in the TP53 mutated subgroup compared to others tumors (p < .05) and in silico analyses of The Cancer Genome Atlas data further indicated that NQO1 mRNA levels were lower in serous compared to endometrioid copy-number high EC.
|
30908539 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the effect of NQO1 and SIRT6 on tumor growth was determined in cell model and orthotopic tumor implantation model.
|
31842909 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Notably, NQO1 inhibitor significantly enhanced the antitumor effects of THC in ESCC PDX tumors.
|
30737573 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous studies have shown that depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC.
|
29291405 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, our findings support that NQO1 displays a paradoxical role in mediating GBM growth in response to tumor suppressor PTEN.
|
30595797 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Developing an effective method for detecting NQO1 activity with high sensitivity and selectivity in tumors holds a great potential for cancer diagnosis, treatment, and management.
|
30487423 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumour tissue was analysed for NQO1 expression.
|
30318513 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H quinone oxidoreductase 1 (NQO1)-dependent antitumor drugs such as β-lapachone (β-lap) are attractive candidates for cancer chemotherapy because several tumors exhibit higher expression of NQO1 than adjacent tissues.
|
29434949 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction to: JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
29880865 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction to: JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
29880796 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A novel anticancer agent RH1 is designed as pro-drug to be activated by NQO1, an enzyme overexpressed in many types of tumors.
|
28879492 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 overexpression correlated to tumor size, venous infiltration and late pTNM stage of HCC.
|
28964792 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer.
|
28346693 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment.
|
27975234 |
2017 |
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Furthermore, NQO1 protects tumour suppressors like p53, p33<sup>ING</sup><sup>1b</sup> and p73 from proteasomal degradation.
|
28236663 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Releasing β-lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase-1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.
|
28833669 |
2017 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This genomic gain was associated with amplification of the NQO1 gene in one tumor biopsy as well as in breast cancer cell lines.
|
26687450 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap-induced radiosensitization.
|
27196777 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 and HO-1 positive tumors showed nearly complete expression of Nrf2 in the nucleus and/or showed partial expression in the nucleus/cytoplasm (nNrf2); however, tumors negative for NQO1 and HO-1 showed almost complete expression of Nrf2 in the cytoplasm and/or partial expression in the nucleus/cytoplasm (cNrf2).
|
27033953 |
2016 |